Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?

Bibliography

• Siegel R, Naishadhma D, Jamal A. Cancer Statistics, 2012. Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong S-J, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
   PubMed Web of Science ®Google Scholar
• Dillman RO, Barth NM, VanderMolen LA, Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 2012;27:337-43
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas LO, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated melanoma. N Engl J Med 2011;364:17-26
   Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15
   PubMed Web of Science ®Google Scholar
• Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011;26:1-64
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Safety and activity anti-PD-L1 antibody inpatients with advanced cancer. N Engl J Med 2012;366:2455-65
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immuotherapy. Clin Cancer Res 2011;17:4550-7
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S, Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
   PubMed Web of Science ®Google Scholar
• Lawson DH, Lee SJ, Tarhini AA, E4697: phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage II-IV melanoma [abstract 8504]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, A phase III randomized, double-blind multiinstitutional trial of vaccinia melanomaoncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 1995;75:34-42
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998;187:69-77
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882-7
   PubMed Web of Science ®Google Scholar
• Sondak VK, Liu PY, Tuthill RJ, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20:2058-66
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH, Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181-90
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Abrams J, Thompson JA, Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2078-85
   PubMed Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF, An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites [abstract 8508]. J Clin Oncol 2007;25:474s
   Web of Science ®Google Scholar
• Weide B, Zelba H, Derhovanessian E, Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012;1835-41
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a grnaulocyte-macrophage colony-stimulating factor-endoding, second-generation oncyloytic Herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009;27:5763-71
   PubMed Web of Science ®Google Scholar
• Clive KS, Tyler Ja, Clifton GT, Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010;9:519-25
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614-21
   PubMed Web of Science ®Google Scholar
• Spitler LE, Weber RW, Allen RE, Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother 2009;32:632-7
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV, Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26
   PubMed Web of Science ®Google Scholar
• Weber J, Sondak VK, Scotland R, Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 2003;97:186-200
   PubMed Web of Science ®Google Scholar
• Steinman R. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96
   PubMed Web of Science ®Google Scholar
• Hart DNJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grunebach F, Schmidt SM, The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol 2008;65:191-9
   PubMed Web of Science ®Google Scholar
• Eubel J, Enk A. Dendritic cell vaccination as a treatment modality for melanoma. Expert Rev Anticancer Ther 2009;9:1631-42
   PubMed Web of Science ®Google Scholar
• Banchereau J, Ueno H, Dhodapkar M, Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type 1 interferon. J Immunother 2005;28:505-16
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase II trial of the DC study group of the DeCOG. Annal Oncol 2006;17:563-70
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, Schreibelt G, Scharenborg NM, Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 2011;60:249-60
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AM, Corthals J, Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011;34:448-56
   PubMed Web of Science ®Google Scholar
• Lopez MN, Pereda C, Segal G, Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing cells. J Clin Oncol 2009;27:945-52
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lee SM, Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med 2010;8:89
   PubMed Web of Science ®Google Scholar
• Trepiakas R, Berntsen A, Hadrup SR, Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytother 2010;12:721-34
   PubMed Web of Science ®Google Scholar
• Hersey P, Menzies SW, Halliday GM, Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004;53:125-34
   PubMed Web of Science ®Google Scholar
• Hersey P, Halliday GM, Farrelly ML, Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother 2008;57:1039-51
   PubMed Web of Science ®Google Scholar
• O'Rourke MG, Johnson M, Lanagan C, Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendrtitic cell vaccine. Cancer Immunol Immunother 2003;52:387-95
   PubMed Web of Science ®Google Scholar
• O'Rourke MG, Johnson MK, Lanagan CM, Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res 2007;17:316-22
   PubMed Web of Science ®Google Scholar
• Redman BG, Chang AE, Whitfield J, Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008;31:591-8
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Petrini M, Fiammenghi L, Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res 2011;21:524-9
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P, Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805-18
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Dang N, Wang X, Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000;23:17-27
   PubMed Web of Science ®Google Scholar
• Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 2004;4:181-98
   PubMed Web of Science ®Google Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines 2004;3:521-7
   PubMedGoogle Scholar
• Berd D, Maguire HC Jr, McCue P, treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, Schuchter LM, Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-70
   PubMed Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E, Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol 2008;26:955-62
   PubMed Web of Science ®Google Scholar
• Kyrgidis A, Tzellos T-G, Triaridis S. Melanoma: stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. J Carcinogen 2010;9:3
   PubMedGoogle Scholar
• Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012;12:133-43
   PubMed Web of Science ®Google Scholar
• Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006;124:1111-15
   PubMed Web of Science ®Google Scholar
• Lapidot T, Sirard C, Vormoor J, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68
   PubMed Web of Science ®Google Scholar
• Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011;17:4942-7
   PubMedGoogle Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60
   PubMed Web of Science ®Google Scholar
• Girouard SD, Murphy GF. Melanoma stem cells: not rare, but well done. Lab Invest 2011;91:647-64
   PubMed Web of Science ®Google Scholar
• Preuss KD, Zwick C, Bormann C, Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43-50
   PubMed Web of Science ®Google Scholar
• Yang F, Yang XF. New concepts in tumor antigens: their significance in future immunotherapies for tumors. Cell Mol Immunol 2005;2:331-41
   PubMed Web of Science ®Google Scholar
• Yang XF. Immunology of stem cells and cancer stem cells. Cell Mol Immunol 2007;4:161-71
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48
   PubMed Web of Science ®Google Scholar
• Schreiber RD. Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun 2005;5(Suppl 1):1
   PubMedGoogle Scholar
• Bifari F, Pacelli L, Krampera M. Immunological properties of embryonic and adult stem cells. World J Stem Cells 2010;2:50-60
   PubMedGoogle Scholar
• Ramgolam K, Lauriol J, Lalou C, Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One 2011;6:e18784
   Web of Science ®Google Scholar
• Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65-9
   Web of Science ®Google Scholar
• Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: a simple method to control fibroblast growth. Clin Biotechnol 1991;3:237-42
   Google Scholar
• Selvan SR, Carbonell DJ, Fowler AW, Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 2010;20:280-92
   PubMed Web of Science ®Google Scholar
• Cornforth AN, Fowler AW, Carbonell DJ, Characterization of interferon-gamma-treated melanoma tumor cells for use in dendritic cell-based immunotherapy. Cancer Biother Radiopharm 2011;26:345-51
   PubMed Web of Science ®Google Scholar
• Civenni G, Walter A, Kobert N, Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res 2011;71:3098-109
   Google Scholar
• Schlagbauer-Wadl H, Jansen B, Muller M, Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer 1999;81:951-5
   PubMed Web of Science ®Google Scholar
• Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark 2007;3:245-50
   PubMedGoogle Scholar
• Dillman RO, DePriest C, de Leon C, Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309-21
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: final Report. Cancer Biother Radiopharm 2009;24:311-19
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med 2006;355:1179-81
   PubMed Web of Science ®Google Scholar
• Cornforth AN, Fowler AW, Carbonell DJ, Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother 2011;60:123-31
   PubMed Web of Science ®Google Scholar
• Dillman RO, Fogel GB, Cornforth AN, Features associated with survival in metastatic melanoma patients treated with patient-specific vaccines consisting of proliferating autologous tumor cells and autologous dendritic cells. Cancer Biother Radiopharm 2011;26:407-15
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, DePriest C, Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012;35:641-9
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nanci AA, Williams ST, Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm 2010;25:553-7
   PubMed Web of Science ®Google Scholar